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Identity 
Other names: DFNA64, DIABLO-S, SMAC, SMAC3 




The gene encompasses 19.86 kb of DNA; 7 exons. 
Transcription 
mRNA 2265 pb; ORF 720 pb. 
Smac promoter contains a functional CRE site which is 
regulated by cAMP for apoptosis modulation 
(Martinez-Velazquez et al., 2007). Another 
transcriptional regulator for Smac is E2F1 which have 
two binding sites in the Smac promoter. Positive 
regulation of Smac by E2F1 results in enhanced 
mitochondria-mediated apoptosis (Xie et al., 2006). 
Protein 
Description 
Precursor 239 aa (27.131 kDa), mature 184 aa (20.765 
kDa). 
- aa 1-55, mitonchondrial targeting sequence (MTS) 
- aa 56-60 (AVPI) IAP-binding motif (IBM). 
Post translational modifications: 
- Ubiquitination, Hip2 (Bae, 2010), Livin (Ma, 2006), 
XIAP (Morizane, 2005; MacFarlane, 2002), cIAP1 (Hu 
and Yang, 2003), cIAP2 (Hu and Yang, 2003), Apollon 
(Hao et al., 2004). 
- Phosphorylation, JNK3 (Park et al., 2007). 
Expression 
Ubiquitously, highest in adult testis and high in heart, 
liver, kidney, spleen, prostate and ovary. Smac mRNA 
is low in brain, lung, thymus and peripheral blood 
leukocytes (Du et al., 2000). 
Localisation 
Mitochondrial (Du et al., 2000), cytosolic, after 
apoptosis activation (Du et al., 2000; Verhagen et al., 
2000). 
Function 
Proapoptotic protein. Smac participates in both 
apoptotic pathways, intrinsic and extrinsic. Mature 
Smac localizes in mitochondria and after an apoptotic 
stimulus is released into the cytosol where it bind IAPs 
and neutralizes its inhibitory action on caspases (Du et 
al., 2000; Verhagen et al., 2000).  
From the IAP family, Smac interacts with and inhibit 
XIAP (Du et al., 2000; Srinivasula et al., 2000), cIAP1 
(Hu and Yang, 2003), cIAP2 (Hu and Yang, 2003), 
Survivin (Song et al., 2003; Kim et al., 2006), Apollon 
(Hao et al., 2004; Qiu and Goldberg, 2005) and ML-
IAP/BIRC7 (Vucic, 2002). Recently, an apoptosis-
independent role for Smac in colon cancer has been 
described. Loss of Smac induces cIAP1 and cIAP2 
upregulation, increased proliferation and activation of 
the NF-kB p65 subunit (Qiu et al., 2012). 
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Structure of Smac gene and its transcripts. 
 
 
Structure of Smac. Smac is a protein of 239 aa. MTS: mitochondrial targeting sequence; IBM: IAP-binding motif; aa: aminoacids. 
 
Homology 
The gene in conserved in chimpanzee, dog, cow, 
mouse, rat, chicken and zebrafish. 
Mutations 
Germinal 
A heterozygous missense mutation, c.377C>T, in 
Smac, is genetically linked to progressive, non-
syndromic, sensorineural hearing loss in an extended 
Chinese DFNA64 family.  
Prediction by molecular modeling localizes this 
mutation at the end of the arch-shaped H1 helix, far 
away from the binding site to IAPs. Although the 
mutation does not alters the apoptotic function of 
Smac, ectopic expression of the mutant induces 
degradation of both, endogenous and mutant Smac 





Significantly elevated levels of Smac were found in 
villous trophoblast in pregnancies complicated by 
preeclampsia in comparison with normal pregnancies.  
This upregulation may be related to increased apoptosis 
in preeclampsia (Heazell et al., 2008). 
Hepatocellular carcinoma 
Note 
mRNA and protein expression of Smac was 
significantly different in tissues of hepatocellular 
carcinoma and non hepatocellular carcinoma tissues. 




Smac protein, by immunohistochemistry analysis, was
significantly upregulated in pancreatic tumours. Smac 
expression was correlated only with pathological grde 
(p<0.05) (Hu et al., 2012). 
Bladder cancer 
Note 
Smac expression is downregulated in bladder cancer, 
this reduced level predicts a worse prognosis (Mizutani 
et al., 2010).  
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Even, the mean serum level of Smac was reduced 2-
fold in bladder cancer patients in comparison  
with normal donors. The mean serum level of Smac 
either was reduced in patients with an advanced stage 
and grade tumor. Lower serum level of smac predicte 
early recurrence in patients with bladder cancer 
(Mizutani et al., 2012). 
Breast cancer 
Note 
Smac expression is reduced in breast cancer and 
inversely correlates with the tumor stage (Pluta et l., 
2011). Smac expression is more prevalent in the HER2 
positive group than negative group (Zhang et al., 2011). 
Additonally, Smac mRNA expression is downregulated 
in breast cancer samples and shows an inverse 
correlation with survivin mRNA expression (Mansour 
et al., 2012). 
Endometrioid endometrial cancer 
Note 
Smac protein expression correlates with tumor grade. 
Negative expression of Smac is a sign of poor 
prognostic in this kind of tumor (Dobrzycka et al., 
2010). 
Ovarian mucinous tumor 
Note 
Smac protein expression is downregulated in this 
tumor. Smac expression inversely correlates with 
Survivin expression. Analysis of subcellular 
localization of Smac demonstrate that Smac protein 
exist mainly in the intermembranal space of the 
mitochondria (Wang et al., 2010). 
Lung cancer 
Note 
Smac mRNA expression is lower in primary lung 
cancer than in normal tissues. In squamous cell 
carcinomas the expression of Smac is more reduced 
than in adenocarcinomas. In tumours of smokers the 
expression of Smac mRNA is lower than in tumours of 
non smokers. Smac expression correlates inversely 
with stage tumour and low expression is sign of worse 
prognostic (Sekimura et al., 2004). 
Non-small cell lung cancer 
Note 
Smac mRNA expression is significantly increased in 
NSCLC tissues in comparison with lung tissue 
(Krepela et al., 2006). In advanced NSCLC high smac 
mRNA expression correlates with longer progression-
free survival (PFS) and overall survival (OS). Smac is 
an independent prognostic factor for OS, but not for 
FPS (Chen et al., 2010). 
Prostate cancer 
Note 
Smac protein is increased in prostate cancer and 
correlates with high Gleason score (sum=8-10) (Grubb 
et al., 2009). 
Colorectal cancer 
Note 
Patients with smac-negative cancer have higher 
incidence of lymph node and distant metastases than 
smac positive-cancer. Negative expression of Smac 
predicts poorer survival and is a prognostic indicator 
independent of Duke's staging and lymph node 
metastases (Endo et al., 2009). 
Testicular germ cell tumours 
Note 
Smac mRNA is downregulated during the development 
and progression of TGCT. While Smac mRNA is 
downregulated XIAP mRNA expression is unchanged, 
and patients with high ratio XIAP:Smac are likely in 
clinical stage III (Kempkensteffen et al., 2007; 
Kempkensteffen et al., 2008b). 
Mycosis fungoides 
Note 
The 12q24.31 region is frequently deleted in early 
stages of MF (Carbone et al., 2008). 
Disease 
The most frequent form of cutaneous T cell lymphoma. 
Renal cell carcinoma 
Note 
Smac protein expression is downregulated in RCC and 
no expression of Smac predicts a worse prognosis 
(Mizutani et al., 2005). Either Smac mRNA expression 
is inversely associated with outcome of RCC patients 
(Kempkensteffen et al., 2008a). 
Cervical cancer 
Note 
Smac mRNA is expressed de novo in cervical cancer, 
although no correlation with any clinical variable was 
found (Espinosa et al., 2004). However, Smac protein 
expression correlates with microvascular density, a 
marker for angiogenesis (Arellano-Llamas et al., 2006). 
B-cell non-Hodgkin and Hodgkin 
lymphomas 
Note 
Smac protein is expressed in almost fifty percent of 
NHL and HL tissues. Smac protein is differentially 
expressed in various NHL types while all HL types 
were positive for Smac (Ren et al., 2006). 
Acute leukemia (AL) 
Note 
Smac mRNA expression is increased in de novo AL 
patients in comparison with normal controls and the
levels decrease in patients at complete remission. In 
relapsed patients the levels of Smac are increased  
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again. Smac expression in AL is related to remission 
rate, patients with high levels of Smac have low 
remission rates. Smac expression could serve like a 
marker of prognosis in AL (Wang and Zhou, 2006). 
Chronic lymphocytic leukemia (CLL) 
Note 
An increased expression of Smac has been observed in 
CLL samples. Possibly, these high levels of Smac in 
CLL could prevent the inhibitory effect of XIAP on 
caspases, since in conditions where XIAP is 
upregulated and apoptosis is prevented, there's no 
caspase inhibition (Schliep et al., 2004; Winkler et al., 
2005). However, downregulation of Smac has been 
also observed in CLL samples. Higher expression of 
IAPs and lower levels of Smac were found in patients 
with progressive disease, compared with those with 
stable CLL (Ren et al., 2006; Grzybowska-Izydorczyk 
et al., 2010). 
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